Want to join the conversation?
$ACOR aims to complete pivotal trials for CVT-301 in Parkinson's disease and PLUMIAZ in seizure clusters this year and if successful, to file NDAs for both in 2017. $ACOR expects these two therapies to have combined peak sales of over $700MM. $ACOR also expects to perform an interim analysis in its Phase 3 trial of dalfampridine.
Impressed with $AMZN’s latest grocery ambitions. The new Amazon Go convenience store, is an absolute game changer.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !